If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
The identification of several specimens as juvenile T. rex has allowed scientists to document ontogenetic changes in the species, estimate the lifespan, and determine how quickly the animals would have grown. The Stygivenator holotype (LACM 28471, the "Jordan theropod"), possibly a juvenile T. rex, is estimated to have weighed only 30 kg (66 lb), while the largest adults, such as FMNH PR2081 (Sue) most likely weighed about 5,650 kg (12,460 lb). Histologic analysis of T. rex bones showed LACM 28471 had aged only 2 years when it died. Sue was initially estimated at 28 years old, an age which was at the time considered close to the maximum for the species, but the most recent studies estimate Sue's age at 27–33 years. Similarly, Trix (RGM 792.000) is estimated to have been at least 30 years old at time of death. Histology has also allowed the age of other specimens to be determined. Growth curves can be developed when the ages of different specimens are plotted on a graph along with their mass. A T. rex growth curve is S-shaped, with juveniles remaining under 1,800 kg (4,000 lb) until approximately 14 years of age, when body size began to increase dramatically. During this rapid growth phase, a young T. rex would gain an average of 600 kg (1,300 lb) a year for the next four years. At 18 years of age, the curve plateaus again, indicating that growth slowed dramatically. For example, only 600 kg (1,300 lb) separated the 28-year-old Sue from a 22-year-old Canadian specimen (RTMP 81.12.1).
Sulfur–sulfur bonds are a structural component used to stiffen rubber, similar to the disulfide bridges that rigidify proteins. In the most common type of industrial "curing" or hardening and strengthening of natural rubber, elemental sulfur is heated with the rubber to the point that chemical reactions form disulfide bridges between isoprene units of the polymer. This process, patented in 1843, made rubber a major industrial product, especially in automobile tires. Because of the heat and sulfur, the process was named vulcanization, after the Roman god of the forge and volcanism.
== History == Salvia hispanica is described and pictured in the Codex Mendoza and the Florentine codex, Aztec codices created between 1540 and 1585. Tribute records from the Mendoza Codex, Matrícula de Tributos, and the Matricula de Huexotzinco (1560), along with colonial cultivation reports and linguistic studies, detail the geographic location of the tributes and provide some geographic specificity to the main S. hispanica-growing regions. Most of the provinces grew the plant, except for areas of lowland coastal tropics and desert, and it was given as an annual tribute by the people to the rulers in 21 of the 38 Aztec provincial states. The traditional cultivation area was in a distinct area that covered parts of north-central Mexico, south to Guatemala. A second and separate area of cultivation, apparently pre-Columbian, was in southern Honduras and Nicaragua. Chia seeds served as a staple food for the Nahuatl (Aztec) cultures. It may have been as important as maize as a food crop. Jesuit chroniclers placed chia as the third-most important crop in the Aztec culture, behind only corn and beans, and ahead of amaranth. Offerings to the Aztec priesthood were often paid in chia seed. In the 21st century, chia is grown and consumed commercially in its native Mexico and Guatemala, as well as Bolivia, Argentina, Ecuador, Nicaragua, Australia, the United Kingdom and the United States. New patented varieties of chia have been developed in Kentucky for cultivation in northern latitudes of the United States.
(2026) identify diagnostic Tasmanian devil specimens from the Juukan 2 Rock Shelter (Pilbara, Western Australia), providing direct evidence of presence of the species in the northwestern Australian mainland during the Late Pleistocene and Holocene, and study chewed and digested bones from the same site accumulated through human activity, interpreted as likely evidence of subsistence of the Tasmanian devils off human activity at the studied site. Watts et al. (2026) study the hindlimb morphology of Hadronomas puckridgi, and interpret its foot with a robust fifth digit as representing an intermediate stage in sthenurine evolution, preceding the appearance of astragalar specializations and loss of the fifth digit in later sthenurines. Evidence from the study of extant and extinct kangaroos, indicating that giant extinct kangaroos were mechanically capable of hopping but it may not have been their primary locomotor mode, is presented by Jones, Jones & Nudds (2026). Couzens, King & Prideaux (2026) report evidence from the study of the fossil record of kangaroos indicative of a progressive increase in tooth enamel thickness in grass-feeding taxa that coincided with expansion of arid habitats in Australia since the late Miocene. Koungoulos, Kerr & O'Connor (2026) describe a manual phalanx bone of a member of the genus Protemnodon from the Taora rockshelter (Papua New Guinea), providing evidence of local survival of members of this genus into the middle Holocene.
Sources: en.wikipedia.org
is fit from experimental data or approximated from the microscopic theory. However, some authors advise caution in applying such simple formulas since non-Newtonian behavior appears in dense suspensions (
== Scientists and inventors == Samuel Bard* (1763), personal physician to George Washington; founder of the Columbia University College of Physicians and Surgeons John Stevens (King's 1768), builder of the first oceangoing steamboat in the U.S. Nicholas Romayne* (1774), physician, president of the Columbia University College of Physicians and Surgeons David Hosack (1790), physician, botanist, educator John Eatton Le Conte (1800), naturalist Samuel Akerly (1804), physician, co-founder of the New York Institute for the Education of the Blind Valentine Mott (1806), surgeon pioneer James Renwick (1807), English-American scientist and engineer, professor of Natural philosophy at Columbia University; father of architect James Renwick Jr. John Brodhead Beck (1813), New York physician Daniel Levy Maduro Peixotto (1816), Dutch-born Jewish American physician, former president of the Willoughby Medical College Henry James Anderson (1818), scientist and educator who participated in the U.S. Dead Sea exploration expedition Alfred Charles Post (1822), surgeon, professor at New York University School of MedicineS Horatio Allen (1823), imported the Stourbridge Lion, first successful steam locomotive to run in the U.S. John Clarkson Jay (1827), physician and notable conchologist, grandson of John Jay Alfred W. Craven (1829), chief engineering of Croton Aqueduct; founding member of the American Society of Civil Engineers Edward S.
Upgrading an existing 35-kilowatt generator to a brand new 200-kilowatt unit. Completely gutting and refinishing three laboratory spaces, which included: Removal of original built-in casework and replacement with modular units that can be moved to fit changing workflows. Replacement of fluorescent lighting with high-efficiency LED panels. Replacement of flaking epoxy floors with brand-new laboratory-grade finish. Addition of auxiliary cooling units for each space to provide the humidity and temperature control required to perform high complexity assays. Installation of new dedicated circuits tied into backup power via a new generator. Restoration and upgrade of the existing HVAC system The new lab was completed on August 1 and became operational on August 24.
Sources: en.wikipedia.org
=== Health experiences === Trans people report multiple negative experiences in health care encounters, contributing to stigmatization of their gender identity. A systematic review conducted by researchers at James Cook University reported that 75.3% of respondents have negative experiences during physician visits when seeking gender identity-based care. Transgender patients also face obstacles to accessing health care that result in adverse effects on their health and quality of life. These include unsafe public spaces, lack of knowledgeable health care professionals, discrimination while accessing care, lack of institutional support, long distances to access treatment, and denial of health care services and health insurance benefits. These often result in trans people avoiding or delaying health care. Trans patients may also avoid treatment as a result of their gender identities being treated as psychological illnesses, or because they fear "discrimination and suboptimal or inappropriate care" as a result of disclosing their gender identities. For instance, after a transgender man seeking medical care in the emergency department was verbally assaulted by the hospital employees, who repeatedly referred to him as a woman, he left the hospital premises before receiving the care he needed. According to a systematic review conducted by Hermaszewska and colleagues, "some transgender people are forced to migrate to countries that offer them better legal protection and wider social acceptance". Others may self-prescribe medication such as gender-affirming hormone therapy.
=== Diagnosis === In 2010, a team from New York described detection of PrPSc in sheep's blood, even when initially present at only one part in one hundred billion (10−11) in sheep's brain tissue. The method combines amplification with a novel technology called surround optical fiber immunoassay (SOFIA) and some specific antibodies against PrPSc. The technique allowed improved detection and testing time for PrPSc. In 2014, a human study showed a nasal brushing method that can accurately detect PrP in the olfactory epithelial cells of people with CJD.
== Dosage and administration == The drug and its generic counterparts are supplied in packages of 12, and available in two strengths: Each B&O Supprettes suppository #15 A contains 16.2 mg (1/4 grain) of belladonna and 30 mg (1/2 grain) of opium. Each B&O Supprettes suppository #16 A contains 16.2 mg of belladonna and 60 mg (1 grain) of opium. The usual dose is one suppository rectally once or twice daily PRN - (as needed), not to exceed four Supprettes in a 24-hour period. In the United States, B&O Supprettes is a Schedule II drug under the Controlled Substances Act of 1970; a written prescription is mandatory, and no refills are permitted. Refrigerated storage is preferable, but not required. Most pharmacies consider B&O Supprettes to be a "special order" item, and as such are not normally kept in inventory. Compounding pharmacies have the capability of producing a generic form of the medication, and can modify the dosage(s) of the active ingredients (for pediatric or elderly patients, and those with chronic kidney disease) or the carrier (usually substituting cocoa butter) to best meet the needs of the patient at the request of the prescriber.
Other fruits that can disperse via water are nipa palm and screw pine. Some fruits have evolved propulsive mechanisms that fling seeds substantial distances – perhaps up to 100 m (330 ft) in the case of the sandbox tree – via explosive dehiscence or other such mechanisms (see impatiens and squirting cucumber).
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.